Evolus (EOLS) Non-Current Deffered Revenue (2017 - 2018)
Evolus' (EOLS) quarterly Non-Current Deffered Revenue came in at $25000.0 in Q4 2018, down 34.21% YoY from $38000.0 in Q4 2017, and down 13.79% on a QoQ basis from $29000.0 in Q3 2018.
Evolus (EOLS) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends
Evolus (EOLS) has 2 years of Non-Current Deffered Revenue data on file, last reported at $25000.0 in Q4 2018.
- Quarterly Non-Current Deffered Revenue fell 34.21% year-over-year to $25000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $25000.0 (down 34.21% YoY) and the FY2018 annual result came in at $25000.0, down 34.21% from the prior year.
- Non-Current Deffered Revenue retreated to $25000.0 in Q4 2018, from $29000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $38000.0 in Q4 2017 to a low of $25000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 25,000.00 |
| Sep 30, 2018 | 29,000.00 |
| Jun 30, 2018 | 32,000.00 |
| Mar 31, 2018 | 35,000.00 |
| Dec 31, 2017 | 38,000.00 |